Similar Associations of Total Adiponectin and High Molecular Weight Adiponectin with Cardio-metabolic Risk Factors in a Population of Overweight and Obese Postmenopausal Women: A MONET Study

Abstract

The aim of the study was to examine the association between total adiponectin and high molecular weight (HMW) adiponectin levels with cardio-metabolic risk factors in a population of sedentary, overweight, and obese postmenopausal women. Cross-sectional study was carried out on 55 nondiabetic sedentary overweight and obese postmenopausal women aged between 50 and 70 years. Insulin sensitivity was assessed by euglycemic-hyperinsulinemic clamp technique. Body composition and visceral fat were measured using dual X-ray absorptiometry and computed tomography, respectively. Other cardio-metabolic risk factors included: plasma lipids, hsC-reactive protein, energy expenditure (doubly labeled water), peak oxygen consumption, muscle strength (using weight training equipment) as well as total and HMW adiponectin. Correlations of total and HMW adiponectin with various cardio-metabolic risk factors were comparable. In addition, regression analysis results showed similar independent predictors of total and HMW adiponectin. Finally, the receiver operator characteristic (ROC) curves for total and HMW adiponectin to predict insulin sensitivity showed no difference between the areas under curve (AUC) (AUC total adiponectin=0.80 [95% CI: 0.66–0.95] versus AUC HMW adiponectin=0.76 [95% CI: 0.60–0.91], p=0.36). The present study indicates that HMW adiponectin does not seem to provide additional information than total adiponectin in relation to cardio-metabolic risk factors in overweight/obese postmenopausal women.

insulin sensitivity - adipokines - body composition - lipid profile - inflammation - energy expenditure

References

• 1 Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors.  End Rev. 2005;  26 439-451
• 2 Whitehead J, Richards A, Hickman I, Macdonald GA, Prins JP. Adiponectin – a key adipokine in the metabolic syndrome.  Diab Ob Met. 2006;  8 264-280
• 3 Koebnick C, Roberts CK, Shaibi GQ, Kelly LA, Lane CJ, Toledo-Corral CM, Davis JN, Ventura EE, Alexander K, Weigensberg MJ, Goran MI. Adiponectin and leptin are independently associated with insulin sensitivity, but not with insulin secretion or beta-cell function in overweight Hispanic adolescents.  Horm Metab Res. 2008;  40 708-712
• 4 Krentz AJ, von Mühlen D, Barrett-Connor E. Adipocytokines, sex hormones, and cardiovascular risk factors in postmenopausal women: factor analysis of the Rancho Bernado study.  Horm Metab Res. 2009;  41 773-777
• 5 Kadowaki T, Yamaushi T, Kubota N Kazuo H, Kohjiro U, Kazuyuki T. Adiponectin and adiponectin receptors in insulin resitance, diabetes, and the metabolic syndrome.  J Clin Inv. 2006;  116 1784-1792
• 6 Weiss M, Orvos J, Flyvbjerg A, Miserez AR, Frytsyk J, Sinnreich R, Kark JD. Adiponectin and lipoprotein particle size.  Diabetes Care. 2009;  32 1317-1319
• 7 Lindsay R, Funahashi T, Hanson R, Matsuzawa Y, Tanaka S, Tataranni A, Knowler W, Krakof J. Adiponectin and development of type 2 diabetes in the Pima Indian population.  Lancet. 2002;  360 57-58
• 8 Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity.  J Biol Chem. 2004;  279 12152-12162
• 9 Chang LC, Huang KC, Wu YW, Kao HL, Chen CL, Lai LP, Hwang JJ, Yang WS. The clinical implications of blood adiponectin in cardio-metabolic disorders.  J Formos Med Assoc. 2009;  108 353-366
• 10 Lu JY, Huang KC, Chang LC, Huang YS, Chi YC, Su TC, Chen CL, Yang WS. Adiponectin: a biomarker of obesity-induced insulin resistance in adipose tissue and beyond.  J Biomed Sci. 2008;  15 565-576
• 11 Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, Hara K, Hada Y, Vasseur F, Froguel P, Kimura S, Nagai R, Kadowaki T. Impaired multimerization of human adiponectin mutants associated with diabetes.  J Biol Chem. 2003;  278 307-316
• 12 Guerre-Millo M. Adiponectin: An update.  Diabetes Metab. 2008;  34 12-18
• 13 Heidemann C, Sun Q, van Dam RM, Meigs JB, Zhang C, Tworoger SS, Mantzoros CS, Hu FB. Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women.  Ann Intern Med. 2008;  149 W307-W366
• 14 von Eynatten M, Lepper PM, Humpert PM. Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise program: comparative evaluation of three assays: response to Bluher et al.  Diabetes Care. 2007;  30 e67
• 15 Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT. Adiponectin multimeric complexes and the metabolic syndrome trait cluster.  Diabetes. 2006;  55 249-259
• 16 Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, Imai Y, Nagai R, Kadowaki T. Measurement of the high-molecular-weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome.  Diabetes Care. 2006;  29 1357-1362
• 17 Kaser S, Tatarczyk T, Stadlmayr A, Ciardi C, Ress C, Tschoner A, Sandhofer A, Paulweber B, Ebenbichler CF, Patsch JR. Effect of obesity and insulin sensitivity on adiponectin isoform distribution.  Eur J Clin Invest. 2008;  38 827-834
• 18 Blüher M, Brennan AM, Kelesidis T, Kratzsch J, Fasshauer M, Kralisch S, Williams CJ, Mantzoros CS. Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays.  Diabetes Care. 2007;  30 280-285
• 19 Komura N, Kihara S, Sonoda M, Kumada M, Fujita K, Hiuge A, Okada T, Nakagawa Y, Tamba S, Kuroda Y, Hayashi N, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Funahashi T, Matsuzawa Y. Osaka CAD Group. Clinical significance of high-molecular weight form of adiponectin in male patients with coronary artery disease.  Circ J. 2008;  72 23-28
• 20 Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin Levels and Risk of Type 2 Diabetes. A Systematic Review and Meta-analysis.  JAMA. 2009;  302 179-188
• 21 Jürimäe J, Jürimäe T, Ring-Dimitriou S, LeMura LM, Arciero PJ, von Duvillard SP. Plasma adiponectin and insulin sensitivity in overweight and normal-weight middle-aged premenopausal women.  Metabolism. 2009;  58 638-643
• 22 Brochu M, Malita MF, Messier V, Doucet E, Strychar I, Lavoie JM, Prud’homme D, Rabasa-Lhoret R. Resistance training does not contribute to improve the metabolic profile after a 6-month weight loss program in overweight and obese postmenopausal women.  J Clin Endocrinol Metab. 2009;  94 3226-3233
• 23 Strychar I, Lavoie ME, Messier L, Karelis AD, Doucet E, Prud’homme D, Fontaine J, Rabasa-Lhoret R. Anthropometric, metabolic, psychosocial, and dietary characteristics of overweight/obese postmenopausal women with a history of weight cycling: A MONET (Montreal Ottawa New Emerging Team) study.  Journal of the American Dietetic Association. 2009;  109 718-724
• 24 Karelis AD, Fontaine J, Messier V, Messier L, Blanchard C, Rabasa-Lhoret R, Strychar I. Psychosocial correlates of cardiorespiratory fitness and muscle strength in overweight and obese post-menopausal women: a MONET study.  J Sports Sci. 2008;  26 935-940
• 25 Brochu M, Mathieu ME, Karelis AD, Doucet E, Lavoie ME, Garrel D, Rabasa-Lhoret R. Contribution of the lean body mass to insulin resistance in postmenopausal women with visceral obesity: A MONET study.  Obesity. 2008;  16 1085-1093
• 26 Messier V, Malita FM, Rabasa-Lhoret R, Brochu M, Karelis AD. Association of cardiorespiratory fitness with insulin sensitivity in overweight and obese postmenopausal women: a Montreal Ottawa New Emerging Team study.  Metabolism. 2008;  57 1293-1298
• 27 Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases.  Radiology. 1983;  148 839-843
• 28 Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, Federspil G, Sechi LA, Vettor R. Plasma adiponectin is decreased in non-alcoholic fatty liver disease.  Eur J Endocrinol. 2009;  152 113-118

Correspondence